- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03816384
Effect of Active Drain Line Clearance on Catheter-Associated Bacteriuria (CAB)
Effect of Active Drain Line Clearance With or Without Silver on Catheter-Associated Bacteriuria (The CAB Study)
Catheter-associated urinary tract infections (CAUTI) are the most common nosocomial infections in critically ill patients and are responsible for high morbidity rates, increased hospital stays and associated costs.
The purpose of this study is to evaluate whether active drain line clearance by the Accuryn Monitoring System reduces the incidence of CAUTI in hospitalized patients requiring catheters.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Urinary tract infection (UTI) is the most common healthcare associated infection (HAI) acquired in hospitals and is estimated to account for approximately 13% of hospital infections in the United States, of which 75% are associated with indwelling urinary catheters. It is estimated that between 12-16% adult inpatients will receive an indwelling urinary catheter during their hospital stay. The rate of catheter-associated UTI (CAUTI) are highest in burn ICUs, followed by inpatient medical wards and neurosurgical ICUs.
The purpose of this study is to evaluate whether active drain line clearance by the Accuryn Monitoring System reduces the incidence of bacteriuria and/or CAUTI in patients requiring catheters for more than 72 hours. This study will also evaluate the efficacy in reducing bacteriuria of the Accuryn silver fabricated silicone catheters.
Undersøgelsestype
Fase
- Ikke anvendelig
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Adult (age ≥ 18)
- Patient or Legally Authorized Representative (LAR) possess the capacity to provide informed consent
- Indication for a urinary bladder catheter (or one currently in place)
- Expected urinary catheter requirement ≥ 72 hours
- No current urinary tract infection
- No current indication for prophylactic antibiotics. If a surgical patient, receive perioperative antibiotics for no greater than 24 hours
Exclusion Criteria:
- Inability to receive a urinary bladder catheter
- Chronic suprapubic catheter in place
- Expected survival < 72 hours
- Receipt of systemic antibiotics within 48 hours of enrollment, other than prophylactic antibiotics given at the time of surgery
- Surgery of the genitourinary tract in the past 6 months prior to admission
- Deemed unfit for the protocol by the investigator for any reason
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: Standard of Care
Patients will receive Standard of Care, commercially available catheter utilized by hospital system.
|
Standard of care urinary drainage system.
|
Eksperimentel: Drain Line Clearance (DLC) Group
Patients will receive FDA-approved Accuryn Monitoring System with active drain line clearance and plain silicone catheter.
|
Urinary drainage system with active drain line clearance and plain silicone catheter.
|
Eksperimentel: Drain Line Clearance and Silver (DLCS) Group
Patients will receive FDA-approved Accuryn Monitoring System with active drain line clearance and silver-doped silicone catheter.
|
Urinary drainage system with active drain line clearance and silver-doped silicone catheter.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Difference in percentage of catheter-associated bacteriuria
Tidsramme: 30 days
|
To study the difference in rate of catheter-associated bacteriuria between SOC catheters and Accuryn silicone or Accuryn silver-doped catheters with active drain line clearance.
|
30 days
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Percentage of asymptomatic (ASB) and symptomatic (CAUTI) bacteriuria
Tidsramme: 30 days
|
To study the incidence and progression of asymptomatic bacteriuria and CAUTI in patients with prolonged foley catheters for greater than 72 hours.
|
30 days
|
Time to Bacteriuria (ASB and CAUTI)
Tidsramme: 30 days
|
To study the progression of asymptomatic bacteriuria and CAUTI in patients with prolonged foley catheters for greater than 72 hours.
|
30 days
|
Urine Culture Comparisons
Tidsramme: 30 days
|
To study the correlation between patient urine cultures and cultures taken from the Foley (Foley tip, urine sampled from collection bag).
|
30 days
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Kevin Foster, MD, Maricopa Integrated Health System (MIHS)
Datoer for undersøgelser
Studer store datoer
Studiestart (Forventet)
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- CRD-06-100548
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Forbrændinger
-
Central Arkansas Veterans Healthcare SystemUnited States Department of Defense; University of ArkansasRekrutteringÅbn Burn Pit ExposureForenede Stater
-
Cairo UniversityRekruttering
-
Cairo UniversityAfsluttet
-
Nepal Health Research CouncilFogarty International Center of the National Institute of HealthRekruttering
-
University of WashingtonFogarty International Center of the National Institute of HealthAfsluttet
-
Arrowhead Regional Medical CenterAfsluttetForbrændinger | Mangel på ascorbinsyre | Væske og elektrolyt ubalance | Forbrændingsgrad anden | Forbrændingsgrad tredje | Burn ShockForenede Stater
Kliniske forsøg med Standard of Care
-
Rhizen Pharmaceuticals SAIncozen Therapeutics Pvt LtdAfsluttet
-
University of Alabama at BirminghamTrukket tilbageFysisk aktivitetForenede Stater
-
University of FloridaPatient-Centered Outcomes Research InstituteAktiv, ikke rekrutterendeProstatakræftForenede Stater
-
NRG OncologyNational Cancer Institute (NCI); Alliance for Clinical Trials in Oncology; Eastern Cooperative Oncology Group og andre samarbejdspartnereRekrutteringHER2-positiv brystkræftForenede Stater, Puerto Rico
-
Berlin Heals GmbHRekrutteringSystolisk venstre ventrikulær dysfunktionSchweiz, Kroatien, Tyskland, Spanien, Serbien, Bosnien-Hercegovina, Bulgarien, Grækenland, Nordmakedonien, Polen, Tjekkiet
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...Neuromed IRCCS; Fondazione IRCCS Istituto Neurologico Nazionale Casmiro... og andre samarbejdspartnereRekrutteringSygeplejerske-patient relationer | Atypisk Parkinsonisme | MSA - Multiple System Atrophy | Sygeplejerske Læge Relationer | PSPItalien
-
The Cleveland ClinicSanten Inc.Aktiv, ikke rekrutterende
-
Henry M. Jackson Foundation for the Advancement...Boston University; Kenya Medical Research Institute; Kenya Ministry of Health og andre samarbejdspartnereAfsluttet
-
Stanford UniversityAfsluttetNeonatal hypoglykæmiForenede Stater